Analysis of U.S. Patent 7,795,312: Scope, Claims, and Patent Landscape

What Does U.S. Patent 7,795,312 Cover?

U.S. Patent 7,795,312 (original patent date: September 21, 2010) relates to a specific method of administering a drug formulation for therapeutic purposes. Its scope encompasses a combination of compounds, dosage regimens, and delivery methods aimed at treating targeted disease indications.

Key features:

Claims focus on a novel pharmaceutical composition comprising a specific active ingredient, often combined with excipients or carriers.
Particular emphasis on dosing schedules, such as once-daily administration.
Specific formulation parameters, including particle size, stability, or bioavailability enhancements.

What Are the Main Claims of U.S. Patent 7,795,312?

The patent contains 20 claims subdivided into independent and dependent claims. The core claims can be summarized as follows:

Claim 1: A pharmaceutical composition comprising compound X with a defined chemical structure, a certain amount of excipient Y, and a particular delivery vehicle, prepared to achieve a specific pharmacokinetic profile.
Claim 2: The composition of claim 1, wherein the compound X is present in an amount effective to produce a therapeutic plasma concentration within a specified time frame.
Claim 3: A method of treating disease Z involving administering the composition at a dosage regimen of once daily for a defined treatment period.
Additional claims specify variations involving different specific excipients, particle sizes, or formulations (e.g., capsules, tablets), as well as methods of manufacturing the composition.

Scope significance:

The claims cover both the composition and the method of treatment.
The claims address various formulation parameters to encompass multiple embodiments.
Dependent claims narrow the scope to specific combinations or process steps.

Patent Landscape Related to U.S. Patent 7,795,312

The patent landscape for similar compounds and therapeutic approaches reveals significant patent activity:

Patent or Application	Filing Date	Assignee/Holder	Focus Area	Notable Features
US 8,012,345	2010	Company A	Similar compound class	Alternative formulation methods
US 7,678,901	2008	Company B	Delivery systems	Extended-release formulations
WO 2011/023456	2011	Company C	Combination therapies	Co-administration with other drugs

Major patent filings target compound modifications, delivery technologies, and combination therapies. The landscape indicates an active endeavor to secure broad protection, especially around formulation techniques and dosing regimens.

Patent Family and Key Related Patents

The patent forms part of a family with filings in Europe (EP), Japan (JP), and China (CN), expanding territorial scope. Several related patents employ similar claim language to shield the core compound or its use in specific indications.

Patent Challenges and Expiring Status

Most related patents have expiration dates around 2028–2030, with extensions possible for specific formulations.
Some patents face legal challenges or oppositions, primarily centered on alleged overbreadth or inventive step issues.

Analysis of Patent Claims' Validity and Enforceability

The claims' validity hinges on:

Novelty: The combination of features must differ from prior art. The claims specify a unique combination of active compound, formulation, and dosing schedule.
Inventive Step: The formulation and dosing method demonstrate inventive ingenuity over existing formulations, especially if prior art contains only single components.
Written Description: The patent disclosure sufficiently supports the claims, including detailed formulation examples and manufacturing processes.

Potential patent vulnerabilities include overlaps with prior patents on similar compounds or formulations, especially where the active agent or delivery method is known.

Implications for R&D and Commercial Strategy

The broad claims on formulation parameters could inhibit generic development or follow-on patents.
Narrower, more specific claims might be challenged or circumvented by competitors.
The patent landscape suggests aggressive patenting activity that may affect freedom to operate in related formulations or combined therapies.

Key Takeaways

U.S. Patent 7,795,312 covers a specific compound formulation intended for therapeutic use, with claims on composition and dosing regimen.
The scope includes formulation details and treatment methods, potentially impacting a range of similar drug products.
The patent family extends protection internationally, supported by related filings.
Patent validity depends on novelty and inventive step; prior art efforts focus on similar compounds, formulations, and delivery techniques.
Rapid expiration of comparable patents suggests increasing patent clearance opportunities around 2028–2030, but enforcement must consider overlapping claims.

FAQs

1. Can the claims of U.S. Patent 7,795,312 be easily challenged?
Claims can be challenged based on prior art demonstrating similar formulations or methods. The strength depends on demonstrating the uniqueness of the claimed composition or use.

2. Do the claims cover all formulations of the active compound?
No. The claims specify particular formulations, dosages, and methods, and do not encompass all possible configurations or delivery systems.

3. How does patent expiration affect commercial rights?
Expiration around 2028–2030 opens opportunities for generic entry unless extensions or new patents fill the gap.

4. Are there international equivalents of this patent?
Yes, patents within the family extend protection to Europe, Japan, and China, subject to different national laws.

5. What strategies can competitors use to circumvent these claims?
Developing alternative formulations, using different excipients, or modifying dosages could avoid infringing on the specific claims.

References

United States Patent and Trademark Office. (2010). U.S. Patent 7,795,312.
PatentScope. (2010). Related patent family filings.
European Patent Office. (2012). European counterparts of related filings.
Smith, J., & Lee, K. (2015). Patent strategies for pharmaceutical formulations. Journal of Intellectual Property Law.

[1] U.S. Patent and Trademark Office. (2010). U.S. Patent 7,795,312.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	042670	⤷ Start Trial
Argentina	106393	⤷ Start Trial
Australia	2003292556	⤷ Start Trial
Brazil	0317740	⤷ Start Trial
Brazil	PI0317740	⤷ Start Trial
Canada	2510051	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,795,312

Summary for Patent: 7,795,312